| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 [I. P., E. T. L., M. G. G., A. V. R., M. C. W.], and BioCarb Incorporated, Gaithersburg, Maryland 20879 [J. L. M.]
B1 and B3 are two newly isolated monoclonal antibodies that react uniformly with the surface of many mucinous carcinomas of the colon, stomach, and ovary but with a limited number of normal tissues, among which are glands of the stomach, epithelia of the trachea and bladder, differentiated epithelium of the esophagus, and small bowel mucin. They also react uniformly with many human tumor cell lines, including MCF7, MDA-MB-468, and HTB20 (breast), A431 (epidermoid), HT29 (colon), HTB33 (cervical), and DU145 (prostate). Immunoprecipitation experiments indicate that B1 and B3 react with epitopes present on a large number of glycoproteins, ranging in molecular weight from >200,000 to <40,000. Using a panel of 37 different carbohydrate residues attached to albumin to form neoglycoproteins, it was found that B1 reacts with Ley and H-type 2 and B3 reacts with Ley, di-Lex, and tri-Lex antigens. Thus, each antibody reacts with a distinct portion of a carbohydrate residue. Because of the limited reactivity of these antibodies with normal tissues, they merit evaluation in the treatment of cancer.
1 To whom requests for reprints should be addressed.
Received 1/22/91. Accepted 5/ 7/91.
This article has been cited by other articles:
|
|
 |
|
  A. Khaibullina, B.-S. Jang, H. Sun, N. Le, S. Yu, V. Frenkel, J. A. Carrasquillo, I. Pastan, K. C.P. Li, and C. H. Paik Pulsed High-Intensity Focused Ultrasound Enhances Uptake of Radiolabeled Monoclonal Antibody to Human Epidermoid Tumor in Nude Mice J. Nucl. Med., February 1, 2008; 49(2): 295 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 PNAS, May 15, 2007; 104(20): 8444 - 8448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, J. Janik, M. W. Brechbiel, and T. A. Waldmann Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors Blood, July 15, 2006; 108(2): 705 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Westwood, M. J. Smyth, M. W. L. Teng, M. Moeller, J. A. Trapani, A. M. Scott, F. E. Smyth, G. A. Cartwright, B. E. Power, D. Honemann, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice PNAS, December 27, 2005; 102(52): 19051 - 19056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yao, M. Zhang, K. Garmestani, D. B. Axworthy, R. W. Mallett, A. R. Fritzberg, L. J. Theodore, P. S. Plascjak, W. C. Eckelman, T. A. Waldmann, et al. Pretargeted {alpha} Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid-Biotin Clin. Cancer Res., May 1, 2004; 10(9): 3137 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yao, M. Zhang, D. B. Axworthy, K. J. Wong, K. Garmestani, L. Park, C. W. Park, R. W. Mallett, L. J. Theodore, E. K. Yau, et al. Radioimmunotherapy of A431 Xenografted Mice with Pretargeted B3 Antibody-Streptavidin and 90Y-labeled 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic Acid (DOTA)-Biotin Cancer Res., October 15, 2002; 62(20): 5755 - 5760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, Z. Yao, K. Garmestani, D. B. Axworthy, Z. Zhang, R. W. Mallett, L. J. Theodore, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha -emitting radionuclide, bismuth 213 Blood, June 17, 2002; 100(1): 208 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Onda, S. Nagata, Y. Tsutsumi, J. J. Vincent, Q.-c. Wang, R. J. Kreitman, B. Lee, and I. Pastan Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity Cancer Res., July 1, 2001; 61(13): 5070 - 5077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Papetti and I. M. Herman Controlling Tumor-Derived and Vascular Endothelial Cell Growth : Role of the 4F2 Cell Surface Antigen Am. J. Pathol., July 1, 2001; 159(1): 165 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Clarke, F.-T. Lee, M. W. Brechbiel, F. E. Smyth, L. J. Old, and A. M. Scott In Vivo Biodistribution of a Humanized Anti-Lewis Y Monoclonal Antibody (hu3S193) in MCF-7 Xenografted BALB/c Nude Mice Cancer Res., September 1, 2000; 60(17): 4804 - 4811. [Abstract] [Full Text]
|
|
|
|
|
|
K. Clarke, F.-T. Lee, M. W. Brechbiel, F. E. Smyth, L. J. Old, and A. M. Scott Therapeutic Efficacy of Anti-Lewisy Humanized 3S193 Radioimmunotherapy in a Breast Cancer Model: Enhanced Activity When Combined with Taxol Chemotherapy Clin. Cancer Res., September 1, 2000; 6(9): 3621 - 3628. [Abstract] [Full Text]
|
|
|
|
|
|
L. H. Pai-Scherf, J. A. Carrasquillo, C. Paik, O. Gansow, M. Whatley, D. Pearson, K. Webber, M. Hamilton, C. Allegra, M. Brechbiel, et al. Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3 Clin. Cancer Res., May 1, 2000; 6(5): 1720 - 1730. [Abstract] [Full Text]
|
|
|
|
|
|
C.-T. Kuan, C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner 125I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts Clin. Cancer Res., June 1, 1999; 5(6): 1539 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Rosok, D. E. Yelton, L. J. Harris, J. Bajorath, K.-E. Hellstrom, I. Hellstrom, G. A. Cruz, K. Kristensson, H. Lin, W. D. Huse, et al. A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab J. Biol. Chem., September 13, 1996; 271(37): 22611 - 22618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Benhar and I. Pastan Identification of Residues That Stabilize the Single-chain Fv of Monoclonal Antibodies B3 J. Biol. Chem., October 6, 1995; 270(40): 23373 - 23380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Pastan and D FitzGerald Recombinant toxins for cancer treatment Science, November 22, 1991; 254(5035): 1173 - 1177. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
